Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99

O. Pagani; D. Klingbiel; T. Ruhstaller; F. Nolè; S. Eppenberger; C. Oehlschlegel; J. Bernhard; P. Brauchli; D. Hess; C. Mamot; E. Munzone; B. Pestalozzi; M. Rabaglio; S. Aebi; K. Ribi; C. Rochlitz; K. Rothgiesser; B. Thürlimann; R. von Moos; K. Zaman; A. Goldhirsch

doi:10.1093/annonc/mdw622

Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99

O. Pagani
, D. Klingbiel
, T. Ruhstaller
, F. Nolè
, S. Eppenberger
, C. Oehlschlegel
, J. Bernhard
, P. Brauchli
, D. Hess
, C. Mamot
, E. Munzone
, B. Pestalozzi
, M. Rabaglio
, S. Aebi
, K. Ribi
, C. Rochlitz
, K. Rothgiesser
, B. Thürlimann
, R. von Moos
, K. Zaman

A. Goldhirsch

Careum Hochschule Gesundheit

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

Originalsprache	Englisch
Seiten (von - bis)	305-312
Fachzeitschrift	Annals of Oncology
Jahrgang	28
Ausgabenummer	2
DOIs	https://doi.org/10.1093/annonc/mdw622
Publikationsstatus	Veröffentlicht - 1 Feb. 2017

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gute Gesundheit und Wohlergehen

Zugriff auf Dokument

10.1093/annonc/mdw622Lizenz: Sonstige

https://linkinghub.elsevier.com/retrieve/pii/S0923753419322288

Dieses zitieren

Pagani, O., Klingbiel, D., Ruhstaller, T., Nolè, F., Eppenberger, S., Oehlschlegel, C., Bernhard, J., Brauchli, P., Hess, D., Mamot, C., Munzone, E., Pestalozzi, B., Rabaglio, M., Aebi, S., Ribi, K., Rochlitz, C., Rothgiesser, K., Thürlimann, B., von Moos, R., ... Goldhirsch, A. (2017). Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99. Annals of Oncology, 28(2), 305-312. https://doi.org/10.1093/annonc/mdw622

@article{d3984b37f67c4821b4f2ee08b387e5ca,

title = "Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99",

author = "O. Pagani and D. Klingbiel and T. Ruhstaller and F. Nol{\`e} and S. Eppenberger and C. Oehlschlegel and J. Bernhard and P. Brauchli and D. Hess and C. Mamot and E. Munzone and B. Pestalozzi and M. Rabaglio and S. Aebi and K. Ribi and C. Rochlitz and K. Rothgiesser and B. Th{\"u}rlimann and \{von Moos\}, R. and K. Zaman and A. Goldhirsch",

year = "2017",

month = feb,

day = "1",

doi = "10.1093/annonc/mdw622",

language = "English",

volume = "28",

pages = "305--312",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Elsevier Ltd.",

number = "2",

}

Pagani, O, Klingbiel, D, Ruhstaller, T, Nolè, F, Eppenberger, S, Oehlschlegel, C, Bernhard, J, Brauchli, P, Hess, D, Mamot, C, Munzone, E, Pestalozzi, B, Rabaglio, M, Aebi, S, Ribi, K, Rochlitz, C, Rothgiesser, K, Thürlimann, B, von Moos, R, Zaman, K & Goldhirsch, A 2017, 'Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99', Annals of Oncology, Jg. 28, Nr. 2, S. 305-312. https://doi.org/10.1093/annonc/mdw622

TY - JOUR

T1 - Do all patients with advanced HER2 positive breast cancer need upfront-chemo when receiving trastuzumab? Randomized phase III trial SAKK 22/99

AU - Pagani, O.

AU - Klingbiel, D.

AU - Ruhstaller, T.

AU - Nolè, F.

AU - Eppenberger, S.

AU - Oehlschlegel, C.

AU - Bernhard, J.

AU - Brauchli, P.

AU - Hess, D.

AU - Mamot, C.

AU - Munzone, E.

AU - Pestalozzi, B.

AU - Rabaglio, M.

AU - Aebi, S.

AU - Ribi, K.

AU - Rochlitz, C.

AU - Rothgiesser, K.

AU - Thürlimann, B.

AU - von Moos, R.

AU - Zaman, K.

AU - Goldhirsch, A.

PY - 2017/2/1

Y1 - 2017/2/1

U2 - 10.1093/annonc/mdw622

DO - 10.1093/annonc/mdw622

M3 - Article

SN - 0923-7534

VL - 28

SP - 305

EP - 312

JO - Annals of Oncology

JF - Annals of Oncology

IS - 2

ER -